ArticleGastroenterology research and practice2025
Histologic Reappraisal and Evaluation of MLH1 Protein Expression in Sessile Serrated Lesions of the Proximal Colon.
Article in Gastroenterology research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Sessile serrated lesions of the appendix: a contemporary review of the literature.BMC gastroenterology · 2026Pooled it
- Histologic Reappraisal and Evaluation of MLH1 Protein Expression in Sessile Serrated Lesions of the Proximal Colon.Gastroenterology research and practice · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Changes in nomenclature and in the criteria for histological diagnosis of the serrated lesions have occurred over the years. Some of these lesions, the sessile serrated lesions (SSLs), progress to adenocarcinoma via suppression of the Objective: Evaluate the frequency of reclassification in histological diagnosis from hyperplastic polyps (HPs) to SSL after reappraisal using the 2019 World Health Organization (WHO) classification, to determine the occurrence of previously undiagnosed dysplasia and to study the expression of the Methodology: Lesions with histological diagnosis of HP, SSL, and SSLD resected by colonoscopies performed between 2005 and 2015 located in the proximal colon were studied. All HPs were submitted for histological review by two pathologists (Examiners 1 and 2), and a third experienced pathologist (Examiner 3) made the final decision when the other examiners did not agree. Interobserver agreement was analyzed. Results: A total of 308 lesions were assessed being 287 with the initial diagnosis of HP and 21 SSL. Thirty-eight (13.3%) lesions with an initial diagnosis of HP had their diagnosis reclassified to SSL. No dysplasia was found. There was a moderate agreement (Kappa 0.52) between Examiners 1 and 2 regarding the diagnosis of SSL. Between Examiners 1 and 3, there was no agreement (Kappa -0.19), and between Examiners 3 and 2, the agreement was poor (Kappa 0.13). All 38 lesions analyzed by immunohistochemistry had Conclusion: Changes in diagnosis from HP to SSL occurred in 13.3%. No dysplasia or lack of MLH1 expression was observed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.